Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
| 8.7 | |
| 8.8 | |
| - | |
| 8.8218 | |
| 8.39 | |
| 2.25-9.18 | |
| 242 M | |
| 27 786 K | |
| 4 607 K | |
| -0.45 | |
| 0.643 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Wall Street Trades Flat On Mixed Producer Inflation; Meme Stocks See Wild Ride, Bitcoin Drops: What's Driving Markets Tuesday? Wall Street is experiencing a subdued trading session, with all major in...
Initial results from the Phase 1b portion of the CHOPIN trial of PHP in combination with ipilimumab plus nivolumab in advanced uveal melanoma in seven patients resulted in 85.7% Best Overall Response ...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
